Liraglutide Cost in Delaware 2026: Cash Price, Insurance, Medicaid and Compounded Options

What Does Liraglutide Actually Cost in Delaware Right Now?

Liraglutide pricing in Delaware spans a wide range depending on whether you pay cash, use insurance, or access a compounding pharmacy. The Novo Nordisk list price for Saxenda (weight management) and Victoza (type 2 diabetes) sits at approximately $1,349 per month before any discounts. Delaware retail pharmacies averaged roughly $900 per month for cash-pay customers in 2026, while licensed 503A compounding pharmacies charge approximately $150 per month for an equivalent dose.

The branded drug liraglutide was approved by the FDA under two indications: Victoza (1.2 mg or 1.8 mg daily) for type 2 diabetes in 2010, and Saxenda (up to 3.0 mg daily) for chronic weight management in 2014 [1][2]. Both are subcutaneous once-daily injections using a prefilled pen. No FDA-approved interchangeable generic exists as of mid-2025, so compounded preparations from 503A-licensed pharmacies remain the primary lower-cost alternative for Delaware residents [3].

Price variation inside Delaware is real. A 30-day supply of Saxenda 18 mg/3 mL (5 pens) carries a GoodRx-quoted retail range of approximately $840 to $960 at Wilmington, Dover, and Newark chain pharmacies, depending on the specific location and the discount program used. Applying a Novo Nordisk savings card or a third-party coupon app typically drops that cash price by 10 to 20 percent for patients without insurance [4].

The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3.0 mg produced a mean weight loss of 8.4% more than placebo over 56 weeks (P<0.001) [5]. That clinical outcome justifies the ongoing prescribing volume in Delaware, but it also puts cost management at the center of patient conversations.

Delaware Medicaid Coverage for Liraglutide

Delaware Medicaid covers liraglutide for both type 2 diabetes and chronic weight management, subject to prior authorization. Patients who meet body mass index thresholds or have a confirmed T2D diagnosis documented in their chart are the strongest candidates for approval.

The Delaware Medical Assistance Program follows a Preferred Drug List (PDL) process administered through the Delaware Division of Medicaid and Medical Assistance (DMMA) [6]. For Victoza in the diabetes indication, prior authorization criteria typically require documented HbA1c above 7.5% on at least one prior oral antidiabetic agent and prescriber attestation that metformin is contraindicated or has failed. For Saxenda in the obesity indication, the PDL generally requires BMI of 30 kg/m² or greater, or BMI of 27 kg/m² with at least one weight-related comorbidity such as hypertension or dyslipidemia [7].

The American Diabetes Association's 2024 Standards of Care state that "GLP-1 receptor agonists with proven cardiovascular benefit are preferred for people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk" [8]. That guideline language strengthens a prior authorization argument when the prescriber documents cardiovascular risk factors.

Processing time for Medicaid PA in Delaware runs 3 to 5 business days for standard requests and 24 hours for expedited urgent requests. Denials can be appealed through DMMA's formal hearing process. Patients on Delaware Medicaid who receive a denial should ask their prescriber to submit a peer-to-peer review, as these overturn approximately 30 to 40% of initial rejections in GLP-1 categories nationally [9].

Is Compounded Liraglutide Legal in Delaware?

Yes. Compounded liraglutide is lawful in Delaware when prepared by a pharmacy licensed under Section 503A of the Federal Food, Drug, and Cosmetic Act and operating in compliance with Delaware Board of Pharmacy rules and USP standards [10].

Section 503A pharmacies produce patient-specific preparations based on a valid prescription from a licensed practitioner. They are not permitted to compound copies of commercially available drugs without a documented patient-specific clinical reason such as allergy to an excipient or a required dose not available in the marketed product [11]. Delaware-based and out-of-state 503A pharmacies that ship into Delaware must hold a non-resident pharmacy license issued by the Delaware Board of Pharmacy [12].

The FDA has not placed liraglutide on its Demonstrably Difficult to Compound (DDITC) list as of mid-2025, meaning 503A pharmacies may compound it lawfully [3]. Compounded liraglutide is not interchangeable with FDA-approved Saxenda or Victoza. The label, concentration, and excipients may differ, and patients should be counseled that the compounded version has not undergone the same FDA efficacy and safety review as the branded product [13].

Cost advantage is substantial. Licensed 503A pharmacies in Delaware and those shipping to DE addresses typically charge $150 to $200 per month for compounded liraglutide, compared to $900 in retail cash-pay and $1,349 at list price. A Delaware telehealth prescriber can write a prescription for the compounded formulation directly, so geography is not a barrier [14].

The HealthRX Delaware Cost Decision Framework (see framework insert below) summarizes how to route a new liraglutide patient across these four access pathways based on insurance status, BMI, and HbA1c.

Which Insurance Plans Cover Liraglutide in Delaware?

Coverage depends on the plan type, the indication (diabetes vs. weight management), and formulary tier. Delaware's largest commercial insurers include Highmark Blue Cross Blue Shield of Delaware, Aetna, UnitedHealthcare, and Cigna, all of which operate ACA marketplace and employer plans in the state [15].

For Victoza in the T2D indication, most commercial plans in Delaware place it on Tier 3 or Tier 4 formulary. A Tier 3 specialty co-pay with a $2,500 annual deductible frequently results in $80 to $200 per month out-of-pocket after the deductible is met. The Novo Nordisk Patient Assistance Program and the NovoCare savings card can reduce commercially insured patients' monthly cost to as little as $25 per month, subject to annual program caps [16].

For Saxenda in the weight-management indication, coverage is significantly narrower. The Affordable Care Act does not mandate obesity drug coverage, so many Delaware employer-sponsored plans explicitly exclude GLP-1 weight-loss agents. Delaware state employee health benefits through Statewide Benefits Office follow the same Highmark BCBS formulary, which does include Saxenda under prior authorization for qualifying BMI and comorbidities [17].

Medicare Part D beneficiaries in Delaware face a different picture. The Inflation Reduction Act of 2022 capped out-of-pocket drug costs at $2,000 per year beginning January 1, 2025, which benefits high-cost drug users [18]. However, Medicare Part D plans are not required to cover obesity-only indications for GLP-1 drugs. Liraglutide prescribed for T2D under the Victoza indication remains the stronger coverage pathway for Medicare patients in Delaware.

A 2023 JAMA Internal Medicine analysis found that patients with commercial insurance faced mean annual out-of-pocket costs of $1,472 for GLP-1 agonists, even with coverage, due to deductible structures [19]. Delaware patients should request a formulary-specific benefit check from their insurer before committing to a prescribing plan.

How Telehealth Prescribing of Liraglutide Works in Delaware

Delaware telehealth law permits prescribing of liraglutide via synchronous audio-video visits without requiring an in-person examination first. Liraglutide is not a controlled substance under the DEA Schedules, so the stricter Ryan Haight Act restrictions that apply to buprenorphine or stimulants do not govern its prescribing [20].

The Delaware Telehealth Access Act, codified at 24 Del. C. § 1769D, requires that the prescribing clinician hold a valid Delaware medical or advanced practice nursing license and that the telehealth encounter meet the same standard of care as an in-person visit [21]. This standard requires the clinician to collect a medical history, document BMI or HbA1c depending on the indication, review contraindications including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and discuss injection technique [22].

The FDA-approved Saxenda prescribing information carries a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies, though human relevance has not been established [2]. Any Delaware telehealth prescriber must document that this risk was discussed and that the patient does not carry known risk factors.

HealthRX clinicians licensed in Delaware conduct intake visits asynchronously combined with a synchronous video review. The prescribing decision follows the Endocrine Society's 2023 Clinical Practice Guideline for obesity pharmacotherapy, which recommends liraglutide 3.0 mg as a first-line pharmacological option for patients with BMI of 30 kg/m² or greater who have not achieved adequate weight loss through lifestyle interventions alone [23].

Understanding the Novo Nordisk Savings Card and Patient Assistance in Delaware

Novo Nordisk operates two distinct programs relevant to Delaware patients: the NovoCare co-pay card for commercially insured patients and the Patient Assistance Program (PAP) for uninsured or underinsured patients who meet income criteria.

The NovoCare savings card for Saxenda caps the commercially insured patient's monthly co-pay at $25 per month for up to 24 months, though the card carries income restrictions and excludes patients using federal insurance including Medicare, Medicaid, TRICARE, and the Veterans Affairs health system [16]. Delaware patients with employer-sponsored or ACA marketplace insurance who earn above 400% of the federal poverty level and whose plan covers Saxenda are typically eligible.

The Novo Nordisk PAP provides free medication to uninsured or underinsured patients with annual household income at or below 400% of the federal poverty level [16]. For a single-person household in 2025, that ceiling is approximately $60,240. Delaware patients apply directly through NovoCare's online portal or by calling 1-877-744-2579. The application requires prescriber participation and proof of income.

A 2022 BMJ Open study found that manufacturer co-pay assistance programs reduced out-of-pocket costs meaningfully for commercially insured patients but provided no benefit to federal program enrollees, effectively creating a two-tiered access structure [24]. Delaware Medicaid patients are excluded from co-pay programs and must rely entirely on the DMMA formulary and PA process outlined above.

GoodRx, RxSaver, and NeedyMeds discount programs are available to any Delaware resident regardless of insurance status. These programs negotiate contract pricing with retail pharmacies and can reduce the cash price of Saxenda by 10 to 30 percent below the sticker price at participating Wilmington, Newark, and Dover locations [4].

Liraglutide vs. Semaglutide in Delaware: A Cost and Efficacy Comparison

Some Delaware patients and prescribers weigh liraglutide against semaglutide (Ozempic, Wegovy) given the availability of compounded semaglutide and a larger efficacy delta in trials. The SCALE Obesity trial (N=3,731) showed liraglutide 3.0 mg produced a 8.0% mean weight loss from baseline at 56 weeks vs. 2.6% for placebo [5]. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% for placebo (P<0.001) [25].

Liraglutide requires once-daily injection; semaglutide for weight management requires once-weekly injection. The dosing burden difference is clinically meaningful for patient adherence. A 2021 Diabetes Care study (N=128 real-world patients) found that once-weekly GLP-1 dosing was associated with significantly higher 6-month persistence than once-daily regimens (78% vs. 54%, P<0.001) [26].

Despite lower absolute efficacy, liraglutide remains a viable first-line option for Delaware patients who prefer a lower-cost entry point through compounding, who have had prior adverse reactions to semaglutide, or whose insurance covers Victoza but not Ozempic. The LEADER cardiovascular outcomes trial (N=9,340) confirmed that liraglutide 1.8 mg reduced major adverse cardiovascular events by 13% vs. placebo in patients with T2D and high cardiovascular risk (hazard ratio 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority) [27], a result that supports its continued use in the T2D cardiovascular risk population.

Side Effect Profile and Monitoring Requirements in Delaware Prescribing

Liraglutide's most common adverse effects are gastrointestinal: nausea occurs in up to 39.3% of patients in the Saxenda clinical program, vomiting in 15.7%, and diarrhea in 20.9% [2]. These effects are dose-dependent and typically peak during the titration phase, which begins at 0.6 mg/day for one week and increases by 0.6 mg increments weekly until reaching the target 3.0 mg dose over five weeks [2].

The FDA prescribing information for Saxenda requires monitoring for pancreatitis, gallbladder disease, and heart rate increases [2]. A NEJM-published post-marketing analysis showed that liraglutide was associated with an approximately 46% higher rate of acute gallbladder disease compared to placebo in pooled SCALE trial data [28]. Delaware prescribers using the telehealth model should include baseline and follow-up liver function panels and lipase testing per standard of care.

Renal function should be assessed before initiation. Liraglutide has not been studied in patients with estimated glomerular filtration rate below 30 mL/min/1.73 m² (severe chronic kidney disease), and the FDA label advises caution in this population [2]. Delaware has a higher-than-average prevalence of CKD, with the CDC estimating that 14.2% of Delaware adults have CKD, compared to 14.9% nationally [29].

Thyroid monitoring: the FDA requires that patients report symptoms of thyroid mass, dysphagia, or hoarseness. No routine calcitonin monitoring is mandated by the FDA label, though some endocrinologists order a baseline calcitonin level as part of their protocol, particularly when a family history of thyroid disease is present [22].

Practical Steps for Delaware Patients Seeking Liraglutide in 2026

Start with an insurance benefit check. Call the member services number on your insurance card and ask specifically whether Saxenda (NDC 00169-4060-11) or Victoza is covered under your current formulary, what tier it sits on, and what the PA requirements are.

If commercially insured and the drug is covered, apply for the NovoCare savings card at novocare.com before the first fill. The card is activated at the pharmacy counter and requires no prior approval wait [16].

If uninsured or on Medicaid, a telehealth visit through a Delaware-licensed GLP-1 prescriber can generate a prescription for compounded liraglutide from a licensed 503A pharmacy. Expect costs of $150 to $200 per month, with the first month often higher due to titration supplies.

If your Delaware Medicaid PA is denied, request a peer-to-peer review within 10 days of the denial letter. Submit the LEADER trial cardiovascular data [27] and the ADA 2024 Standards of Care [8] alongside your prescriber's clinical notes to strengthen the appeal.

Baseline labs before starting: fasting glucose, HbA1c, comprehensive metabolic panel including lipase, thyroid-stimulating hormone, and a fasting lipid panel. Most Delaware telehealth platforms can order these through Quest Diagnostics or LabCorp with a patient service center in Wilmington or Dover.

At the 16-week mark, the Saxenda clinical program used 16 weeks as an efficacy checkpoint: patients who had not lost at least 4% of baseline body weight were considered non-responders and discontinued [2]. Delaware prescribers should apply this same checkpoint regardless of whether the patient is using the branded or compounded formulation.